Compare · BTCY vs DXCM
BTCY vs DXCM
Side-by-side comparison of Biotricity Inc. (BTCY) and DexCom Inc. (DXCM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BTCY and DXCM operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $28.08B, about 196.3x BTCY ($143.0M).
- Over the past year, BTCY is up 0.0% and DXCM is down 15.1% - BTCY leads by 15.1 points.
- DXCM has been more active in the news (30 items in the past 4 weeks vs 1 for BTCY).
- DXCM has more recent analyst coverage (25 ratings vs 3 for BTCY).
- Company
- Biotricity Inc.
- DexCom Inc.
- Price
- $0.48-25.30%
- $72.74-0.92%
- Market cap
- $143.0M
- $28.08B
- 1M return
- +0.00%
- +21.17%
- 1Y return
- +0.00%
- -15.06%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- News (4w)
- 1
- 30
- Recent ratings
- 3
- 25
Biotricity Inc.
Biotricity, Inc., medical technology company, provides biometric data monitoring solutions primarily in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated electrocardiogram (ECG) device and software solution. The company is based in Redwood City, California.
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Latest BTCY
- SEC Form PRE 14C filed by Biotricity Inc.
- Biotricity Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- Biotricity Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form 10-Q filed by Biotricity Inc.
- Biotricity Delivers Strong Q3 Fiscal 2026 Performance, Growing Revenue Momentum and Expanding EBITDA
- Biotricity to Announce Continued Growth in Fiscal 2026 Third Quarter Financial Results and Business Update Call on February 11th
- SEC Form S-1 filed by Biotricity Inc.
- Biotricity Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Biotricity Strengthens Path to Scalable Profitability with Sustained Margins & Operational Efficiency in Second Quarter Fiscal 2026
- SEC Form 10-Q filed by Biotricity Inc.
Latest DXCM
- Dexcom Releases Customer Advisory Council Report, Outlining Ongoing Commitments to Enhancing Product Performance and User Experience
- Director Altman Steven R was granted 5,565 shares (SEC Form 4)
- Director Augustinos Nicholas was granted 5,575 shares (SEC Form 4)
- Director Malady Kyle was granted 5,575 shares, increasing direct ownership by 25% to 28,242 units (SEC Form 4)
- Director Heller Bridgette P was granted 5,575 shares, increasing direct ownership by 22% to 30,582 units (SEC Form 4)
- Director Osterloh Albert Frederick Iv was granted 1,630 shares, increasing direct ownership by 23% to 8,691 units (SEC Form 4)
- Director Foletta Mark G was granted 6,331 shares (SEC Form 4)
- Director Driscoll Rimma was granted 5,605 shares, increasing direct ownership by 48% to 17,319 units (SEC Form 4)
- Director Ashley Euan A. was granted 5,565 shares, increasing direct ownership by 78% to 12,731 units (SEC Form 4)
- Director Collins Richard Alexander was granted 5,605 shares (SEC Form 4)